Sunday, August 14, 2022 8:56:04 PM
<<Jennifer Kim with Cantor Fitzgerald. Please go ahead.
Hey, everyone.... And then my second question is broader, with the Trans Ova divestiture, has anything changed in your mind in terms of portfolio prioritization and added flexibility to explore opportunities that you weren't able necessarily to consider beforehand?
Answer; As Harry mentioned, we have a solid runway well to the fourth quarter of 2023, which has allowed us to basically go through our – some of the clinical timelines that we have for reporting the data. And I think that's going to be very good. And we basically do not have to take anything from the financial strength that we have, or I should say the money that we have, currently that is dedicated to our clinical trial and be diverting this for our convertible notes. And that's – obviously it's a huge, I think, pressure off at this point, especially during this financial times and not diluting our investor base. So we are very happy about that.
We have prioritized portfolio as we have mentioned in our slides and according to the three pillar of a strategy that we have and we mentioned for instance, even in regard to our AG019, which is a very exciting program for a type 1 diabetes, we feel that this has served best with partnership, which the discussions on our partnerships are ongoing and we look forward to report on that in the near future.>>
Recent PGEN News
- Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Precigen Reports Full Year 2023 Financial Results and Business Updates • PR Newswire (US) • 03/19/2024 08:05:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th • PR Newswire (US) • 03/05/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/27/2024 06:48:40 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:00:22 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:20:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:25:09 PM
- Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/06/2024 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/18/2024 05:15:14 AM
- Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission • PR Newswire (US) • 01/16/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:39:30 PM
- Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/08/2024 01:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 10:26:37 PM
- Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 12/18/2023 09:05:00 PM
- Precigen to Participate in the JMP Securities Hematology and Oncology Summit • PR Newswire (US) • 11/29/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:08:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:07:37 PM
- Precigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs • PR Newswire (US) • 11/09/2023 09:55:00 PM
- Precigen to Participate in the Stifel 2023 Healthcare Conference • PR Newswire (US) • 11/07/2023 09:05:00 PM
- Precigen to Participate in Upcoming Leading Investor and Industry Conferences • PR Newswire (US) • 09/19/2023 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/25/2023 11:04:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/25/2023 11:03:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/25/2023 11:01:56 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM